CAS 857890-39-2
:Lenvatinib mesylate
Description:
Lenvatinib mesylate is a small molecule tyrosine kinase inhibitor primarily used in the treatment of certain types of cancer, including thyroid cancer and renal cell carcinoma. It works by inhibiting multiple receptor tyrosine kinases involved in tumor growth and angiogenesis, such as VEGFR, FGFR, PDGFR, and RET. The substance is characterized by its mesylate salt form, which enhances its solubility and bioavailability. Lenvatinib mesylate is typically administered orally and is known for its pharmacokinetic properties, including a relatively long half-life, allowing for once-daily dosing. Common side effects may include hypertension, fatigue, diarrhea, and decreased appetite. The compound is classified as a targeted therapy, reflecting its mechanism of action that specifically disrupts cancer cell signaling pathways. Its development has been a significant advancement in oncology, providing a therapeutic option for patients with advanced malignancies. As with any medication, careful monitoring and management of side effects are essential during treatment.
Formula:C21H19ClN4O4·CH4O3S
InChI:InChI=1S/C21H19ClN4O4.CH4O3S/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11;1-5(2,3)4/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28);1H3,(H,2,3,4)
InChI key:InChIKey=HWLFIUUAYLEFCT-UHFFFAOYSA-N
SMILES:O(C=1C2=C(C=C(OC)C(C(N)=O)=C2)N=CC1)C3=CC(Cl)=C(NC(NC4CC4)=O)C=C3.S(C)(=O)(=O)O
Synonyms:- 4-(3-Chloro-4-(Cyclopropylaminocarbonyl)Aminophenoxy)-7-Methoxy-6-Quinolinecarboxamide Mesylate
- 4-[3-Chloro-4-[(cyclopropylaminocarbonyl)amino]phenoxy]-7-methoxy-6-quinolinecarboxamide mesylate
- 6-Quinolinecarboxamide, 4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-, methanesulfonate (1:1)
- 6-Quinolinecarboxamide,4-[3-chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-,monomethanesulfonate
- E 7080 mesylate
- Kisplyx
- Lenvatinib methanesulfonate
- Lenvima
- Lenvatinib mesylate
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Found 12 products.
lenvatinib Mesylate
CAS:Formula:C22H23ClN4O7SPurity:99%Color and Shape:SolidMolecular weight:522.9586Lenvatinib mesylate
CAS:4-(3-Chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxamide methanesulfonateFormula:C22H23ClN4O7SPurity:99%Molecular weight:522.96Lenvatinib mesylate
CAS:Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.Formula:C22H23ClN4O7SPurity:99.03% - 99.79%Color and Shape:SolidMolecular weight:522.96Lenvatinib Mesylate
CAS:Controlled ProductFormula:C21H19ClN4O4·CH4O3SColor and Shape:NeatMolecular weight:522.959Lenvatinib mesylate - Bio-X ™
CAS:Lenvatinib is an anti-cancer drug that is a multi-kinase inhibitor for VEGFR1, VEGFR2 and VEGFR. It has been shown to be effective against several cancers such as thyroid cancer and is currently in clinical trials for the treatment of leukaemia and prostate cancer. Furthermore, Lenvatinib also inhibits the activity of other protein kinases, including those involved in inflammatory responses.Formula:C22H23ClN4O7SPurity:Min. 95%Color and Shape:PowderMolecular weight:522.96 g/molLenvatinib mesylate
CAS:VEGFR2 tyrosine kinase inhibitorFormula:C22H23ClN4O7SPurity:Min. 98 Area-%Color and Shape:PowderMolecular weight:522.96 g/mol
